Blueprint Medicines Corporation
BPMC
Rank in Stocks
#2358
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to... Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
Share Price
$129.46
Last synced: 2025-07-18
Market Cap
$8.36B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Blueprint Medicines Corporation (BPMC)
Category
Healthcare
Operating Margin for Blueprint Medicines Corporation (BPMC)
Operating Margin as of October 2026 TTM: -41.67%
According to Blueprint Medicines Corporation latest financial reports and stock price the company's current Operating Margin (TTM) is -41.67%. At the end of 2023 the company had an Operating Margin of -194.99%.
Operating Margin history for Blueprint Medicines Corporation from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -41.67% | 0.00% |
| 2024 | -41.67% | -78.63% |
| 2023 | -194.99% | -27.56% |
| 2022 | -269.19% | -25.25% |
| 2021 | -360.10% | -1,045.89% |
| 2020 | 38.07% | -106.91% |
| 2019 | -551.16% | -0.67% |
| 2018 | -554.86% | -20.47% |
| 2017 | -697.64% | 163.22% |
| 2016 | -265.04% | -43.01% |
| 2015 | -465.10% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.93% |
US
|
|
| -149.01% | -96.42% |
US
|
|
| 25.57% | -100.61% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.69% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.